A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
681actual
Sites
89
Countries
Argentina, Brazil, Chile +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-05-21 | actual | When the study began enrolling |
| Primary completion | 2025-07-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-10 | estimated | The whole study's end, after follow-up |
| First posted | 2021-03-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Clear Cell Renal Cell Carcinoma
Interventions
- Biological: Nivolumab and rHuPH20 — also filed as BMS-986298
- Biological: Nivolumab — also filed as Opdivo, BMS-936558
Primary outcomes
what the primary-completion date above is the date OFTime-averaged serum concentration over 28 days (Cavgd28)
measured Up to 28 days
Trough serum concentration at steady-state (Cminss)
measured Up to 4 months
Publications
- PMID 39288844 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed